国医医联完成PreB轮融资，国门同翔基金领投

Core Insights - Beijing Guoyi Yilian Health Technology Co., Ltd. has received an investment from the Beijing Guomen Tongxiang Equity Investment Fund, with a valuation of 200 million yuan [1][3] - The collaboration aims to enhance the transformation system of traditional Chinese medicine (TCM) clinical achievements in the Shunyi District, creating a demonstration center for TCM results [1][3] Company Overview - Guoyi Yilian focuses on the transformation of cutting-edge technologies in the biomedicine and medical device sectors, showcasing strong technological innovation capabilities and clear market development prospects [3] - The company has established significant technical advantages and a comprehensive business layout in the transdermal drug delivery field, serving nearly 10,000 hospitals nationwide [3] Investment and Development - The core transdermal drug delivery project has secured Series A funding from Tongrentang Fund in 2024, highlighting its technological advancement and commercial potential [3] - The investment from the Beijing Guomen Tongxiang Equity Investment Fund is expected to facilitate the company's technological implementation, industry integration, and service upgrades in the region [3] Strategic Goals - The funding will focus on building TCM achievement transformation scenarios in Shunyi District, enhancing the accessibility and precision of TCM services [3] - The company aims to accelerate the large-scale application of TCM clinical results through an integrated transformation system of "technology + operations + channels" [3]